Primary Medical Care Group
Mental Health Group, Community Clinical Sciences Division, University of Southampton School of Medicine, Southampton
Health Economics Research Group, Brunel University, London
Mental Health Group, Clinical Neurosciences Division, University of Southampton School of Medicine
Three Swans Surgery, Salisbury
Primary Medical Care Group, Community Clinical Sciences Division, University of Southampton School of Medicine
Faculty of Health and Sciences, Staffordshire University, Stoke on Trent
Health Care Research Unit, Community Clinical Sciences Division, University of Southampton School of Medicine
School for Health and Related Research, University of Sheffield
Brighton and Sussex Medical School, Brighton
Health Economics Research Group, Brunel University, London
Mental Health Group, Community Clinical Sciences Division, University of Southampton School of Medicine, Southampton, UK
Correspondence: Professor Tony Kendrick, Primary Medical Care Group, Community Clinical Sciences Division, University of Southampton Medical School, Aldermoor Health Centre, Southampton SO16 5ST, UK.Tel: +44 (0)23 8024 1050; fax: +44 (0)23 8070 1125; e-mail: ark1{at}soton.ac.uk
Declaration of interest T.K., R.P., D.B. and C.T. have received funds from major drug companies which are unrelated to the funding of this study.Funding detailed in Acknowledgements.
Background The cost-effectiveness of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) has not been compared in a prospective study in primary care.
Aims To determine the relative cost-effectiveness of TCAs, SSRIs and lofepramine in UKprimary care.
Method An open-label, three-arm randomised trial with a preference arm. Practitioners referred 327 patients with incident depression.
Results No significant differences were found in effectiveness or cost-effectiveness. The numbers of depression-free weeks over12 months (on the Hospital Anxiety and Depression Scale) were 25.3 (95% CI 21.329.0) for TCAs, 28.3 (95% CI 24.332.2) for SSRIs and 24.6 (95% CI 20.628.9) for lofepramine. Mean health service costs per patient were £762 (95% CI 5531059) for TCAs, £875 (95% CI 6751355) for SSRIs and £867 (95% CI 6341521) for lofepramine.Cost-effectiveness acceptability curves suggested SSRIs were mostcost-effective (with a probability of up to 0.6).
Conclusions The findings support a policy of recommending SSRIs as first-choice antidepressants in primary care.
Related articles in BJP: